These data demonstrate the efficacy of 67Cu-labeled SAR-BBN in an animal model and, combined with human data currently being generated on [64Cu]Cu-SAR-BBN, has promising potential as a theranostic pair for clinical translation in cancers expressing GRPR such as breast cancer, glioblastoma, and prostate cancer. This evidence concerns the gene GRPR and prostate carcinoma.